心血管生物学中的基因组编辑。
Genome Editing in Cardiovascular Biology.
机构信息
From the Stanford Cardiovascular Institute, CA (T.S., J.C.W.); Department of Medicine, Division of Cardiology (T.S., J.S.W.); Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine (M.P.); and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, CA (M.P., J.C.W.).
出版信息
Circ Res. 2017 Mar 3;120(5):778-780. doi: 10.1161/CIRCRESAHA.116.310197.
Abstract
Genome editing has emerged as a powerful tool in research and is entering the stage of therapeutic applications. In the cardiovascular field, its role in basic and translational research is well established. However, biological and technical barriers currently hamper the therapeutic potential of genome editing for cardiovascular diseases. This viewpoint discusses possible routes for promoting therapeutic use of genome editing in the cardiovascular system.
摘要
基因组编辑已成为研究领域中的强大工具，并正进入治疗应用阶段。在心血管领域，它在基础和转化研究中的作用已得到充分证实。然而，目前生物学和技术方面的障碍限制了基因组编辑在心血管疾病治疗中的潜力。本文观点探讨了促进基因组编辑在心血管系统中治疗用途的可能途径。
相似文献
1
Genome Editing in Cardiovascular Biology.心血管生物学中的基因组编辑。
Circ Res. 2017 Mar 3;120(5):778-780. doi: 10.1161/CIRCRESAHA.116.310197.
2
Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.近年来遗传性心血管疾病的基因组编辑方法研究进展
Curr Cardiol Rep. 2018 Jun 2;20(7):58. doi: 10.1007/s11886-018-0998-3.
3
CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening.CRISPR/Cas9介导的人类干细胞来源心肌细胞基因组编辑：在心血管疾病建模和心脏毒性筛查中的应用
Drug Discov Today Technol. 2018 Aug;28:13-21. doi: 10.1016/j.ddtec.2018.06.002. Epub 2018 Jun 25.
4
Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.基因组编辑和诱导多能干细胞技术在心血管疾病个体化研究中的应用。
Curr Cardiol Rep. 2018 Apr 17;20(6):38. doi: 10.1007/s11886-018-0984-9.
5
Future challenges for patient-specific induced pluripotent stem cells in cardiovascular medicine.心血管医学中患者特异性诱导多能干细胞面临的未来挑战。
Expert Rev Cardiovasc Ther. 2012 Aug;10(8):943-5. doi: 10.1586/erc.12.88.
6
At the Heart of Genome Editing and Cardiovascular Diseases.基因组编辑与心血管疾病的核心
Circ Res. 2018 Jul 6;123(2):221-223. doi: 10.1161/CIRCRESAHA.118.312676.
7
How genome editing could be used in the treatment of cardiovascular diseases.基因组编辑如何用于治疗心血管疾病。
Per Med. 2018 Mar;15(2):67-69. doi: 10.2217/pme-2017-0078. Epub 2018 Feb 2.
8
Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium.多能干细胞衍生的心肌细胞的旁分泌作用挽救受损心肌。
Circ Res. 2017 Sep 1;121(6):e22-e36. doi: 10.1161/CIRCRESAHA.117.310803. Epub 2017 Jul 25.
9
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.CRISPR-Cas9：一种用于诱导多能干细胞基因编辑的有前景的工具。
Korean J Intern Med. 2017 Jan;32(1):42-61. doi: 10.3904/kjim.2016.198. Epub 2017 Jan 1.
10
The Implications of CRISPR-Cas9 Genome Editing for IR.CRISPR-Cas9基因组编辑对胰岛素抵抗的影响。
J Vasc Interv Radiol. 2018 Sep;29(9):1264-1267.e1. doi: 10.1016/j.jvir.2018.02.027.
引用本文的文献
1
The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review.心脏黏液瘤作为有限的心脏增殖/再生潜能的可能后果的良性性质和罕见发生：系统评价。
BMC Cancer. 2023 Dec 18;23(1):1245. doi: 10.1186/s12885-023-11723-3.
2
CRISPR/Cas9 technology: applications in oocytes and early embryos.CRISPR/Cas9 技术：在卵母细胞和早期胚胎中的应用。
J Transl Med. 2023 Oct 24;21(1):746. doi: 10.1186/s12967-023-04610-9.
3
Atherosclerotic Disease: Pathogenesis and Approaches to Management.动脉粥样硬化性疾病：发病机制与治疗方法。
Med Clin North Am. 2023 Sep;107(5):793-805. doi: 10.1016/j.mcna.2023.04.004. Epub 2023 Jun 1.
4
Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.利用 CRISPR-Cas9 外显子缺失策略生产杜氏肌营养不良症细胞模型。
Mol Cell Biochem. 2024 May;479(5):1027-1040. doi: 10.1007/s11010-023-04759-3. Epub 2023 Jun 8.
5
CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy.利用 CRISPR-Cas9 技术编辑 TLR4 以改善心脏细胞治疗效果。
Sci Rep. 2023 Mar 18;13(1):4481. doi: 10.1038/s41598-023-31286-4.
6
Genome Editing and Myocardial Development.基因组编辑与心肌发育
Adv Exp Med Biol. 2023;1396:53-73. doi: 10.1007/978-981-19-5642-3_4.
7
Global research trends in atherosclerosis: A bibliometric and visualized study.动脉粥样硬化的全球研究趋势：一项文献计量学与可视化研究
Front Cardiovasc Med. 2022 Aug 23;9:956482. doi: 10.3389/fcvm.2022.956482. eCollection 2022.
8
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy.癌症治疗相关心力衰竭发生发展的机制与见解
Children (Basel). 2021 Sep 21;8(9):829. doi: 10.3390/children8090829.
9
The changing landscape of atherosclerosis.动脉粥样硬化的变化格局。
Nature. 2021 Apr;592(7855):524-533. doi: 10.1038/s41586-021-03392-8. Epub 2021 Apr 21.
10
Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery.人多能干细胞来源的心脏细胞：在疾病建模、细胞治疗和药物发现中的应用。
Front Cell Dev Biol. 2021 Apr 1;9:655161. doi: 10.3389/fcell.2021.655161. eCollection 2021.
本文引用的文献
1
The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals.来自342415名个体关联研究的血压调节及其靶器官遗传学。
Nat Genet. 2016 Oct;48(10):1171-1184. doi: 10.1038/ng.3667. Epub 2016 Sep 12.
2
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.解决心血管疾病干细胞再生治疗主要临床障碍的潜在策略：综述。
JAMA Cardiol. 2016 Nov 1;1(8):953-962. doi: 10.1001/jamacardio.2016.2750.
3
Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.人类诱导多能干细胞作为个性化精准心血管医学的一个平台
Physiol Rev. 2016 Jul;96(3):1093-126. doi: 10.1152/physrev.00036.2015.
4
Duchenne muscular dystrophy: CRISPR/Cas9 treatment.杜氏肌营养不良症：CRISPR/Cas9 治疗。
Cell Res. 2016 May;26(5):513-4. doi: 10.1038/cr.2016.28. Epub 2016 Mar 1.
5
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.一种双腺相关病毒（AAV）系统能够在新生小鼠中实现Cas9介导的代谢性肝病矫正。
Nat Biotechnol. 2016 Mar;34(3):334-8. doi: 10.1038/nbt.3469. Epub 2016 Feb 1.
6
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.工程化心脏组织与诱导多能干细胞：用于疾病建模、药物筛选及转化研究的宏观与微观结构
Adv Drug Deliv Rev. 2016 Jan 15;96:234-244. doi: 10.1016/j.addr.2015.09.010. Epub 2015 Sep 30.
7
A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.一项基于千人基因组计划的冠心病全基因组关联荟萃分析。
Nat Genet. 2015 Oct;47(10):1121-1130. doi: 10.1038/ng.3396. Epub 2015 Sep 7.
8
Hurdles to clinical translation of human induced pluripotent stem cells.人类诱导多能干细胞临床转化面临的障碍。
J Clin Invest. 2015 Jul 1;125(7):2551-7. doi: 10.1172/JCI80575.
9
Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.人胚胎干细胞来源的心肌祖细胞治疗严重心力衰竭：首例临床病例报告。
Eur Heart J. 2015 Aug 7;36(30):2011-7. doi: 10.1093/eurheartj/ehv189. Epub 2015 May 19.
10
In vivo genome editing using Staphylococcus aureus Cas9.使用金黄色葡萄球菌Cas9进行体内基因组编辑。
Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1.
Zotero 插件